论文部分内容阅读
目的观察依那普利联合人胰岛素治疗糖尿病肾病对尿蛋白排泄率(UAER)的影响。方法将220例糖尿病肾病患者随机分为研究组和对照组各110例,对照组患者给予降脂抗凝等基础治疗,研究组在对照组治疗的基础上给予依那普利和人胰岛素,治疗3个月后比较2组临床疗效,并观察2组患者UAER、白蛋白(Alb)、尿素氮(BUN)、内生肌酐清除率(Ccr)、血肌酐(Scr)变化。结果研究组治疗总有效率为99.1%高于对照组的90.00%,差异均有统计学意义(P<0.05),治疗后2组患者UAER优于治疗前(P<0.05),且研究组优于对照组,差异均有统计学意义(P<0.05);其他指标虽然有所改善,但差异无统计学意义(P>0.05)。结论依那普利与人胰岛素联合治疗糖尿病肾病能够显著降低糖尿病肾病患者的蛋白排泄率,治疗效果显著,值得临床上广泛推广应用。
Objective To observe the effect of enalaprol combined with human insulin on urinary protein excretion (UAER) in diabetic nephropathy. Methods 220 cases of diabetic nephropathy were randomly divided into study group and control group of 110 cases, the control group of patients given basic treatment of lipid-lowering anticoagulation, the study group in the control group based on the treatment of enalapril and human insulin, treatment 3 After two months, the clinical efficacy was compared between the two groups. The changes of UAER, Alb, BUN, Ccr and Scr in two groups were observed. Results The total effective rate of the study group was 99.1%, which was significantly higher than that of the control group (90.00%, P <0.05). The UAER of the two groups was better than that before treatment (P <0.05) In the control group, the difference was statistically significant (P <0.05); other indicators improved, but the difference was not statistically significant (P> 0.05). Conclusion Enalapril combined with human insulin treatment of diabetic nephropathy can significantly reduce the proteinuria in patients with diabetic nephropathy, the treatment effect is significant, it is widely used in clinical practice.